Paraneoplastic opsoclonus myoclonus syndrome associated with inflammatory myofibroblastic tumor in a pediatric patient

Opsoclonus myoclonus syndrome (OMS) is a rare neurological syndrome caused by a paraneoplastic autoimmune process that affects children with neuroblastic tumors. Treatment includes corticosteroids, intravenous gamma globulin (IVIG), rituximab, and other immunosuppressive therapies. Here, we describe...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2020-08, Vol.67 (8), p.e28218-n/a
Main Authors: Gerstle, Karyn, Siddiqui, Amir, Schulte, Jefree J., Cohn, Susan L.
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - administration & dosage
anaplastic lymphoma kinase
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Autoimmune diseases
Child, Preschool
Children
Corticosteroids
Follow-Up Studies
Globulins
Hematology
Humans
Immunoglobulins
Immunoglobulins, Intravenous - administration & dosage
Immunosuppressive agents
Immunosuppressive Agents - administration & dosage
Inflammation
inflammatory myofibroblastic tumor
Intravenous administration
IVIG
Male
Monoclonal antibodies
Myoclonus
Neoplasms, Muscle Tissue - pathology
Neoplasms, Muscle Tissue - therapy
Neuroblastoma
Neuromuscular diseases
Oncology
opsoclonus myoclonus syndrome
Opsoclonus-Myoclonus Syndrome - pathology
Opsoclonus-Myoclonus Syndrome - therapy
Paraneoplastic syndrome
Patients
Pediatrics
Rituximab
Rituximab - administration & dosage
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Opsoclonus myoclonus syndrome (OMS) is a rare neurological syndrome caused by a paraneoplastic autoimmune process that affects children with neuroblastic tumors. Treatment includes corticosteroids, intravenous gamma globulin (IVIG), rituximab, and other immunosuppressive therapies. Here, we describe a patient diagnosed with OMS associated with a localized inflammatory myofibroblastic tumor. The patient has no evidence of tumor recurrence following surgical resection with 8‐month follow‐up. The neurologic symptoms resolved with corticosteroids and IVIG. This case demonstrates that in children, neoplasms other than neuroblastoma may be associated with this paraneoplastic syndrome, and highlights the importance of evaluating patients with OMS for underlying malignancies.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.28218